Topics

FDA Approves Luspatercept for Beta Thalassemia–Associated Anemia

13:31 EST 8 Nov 2019 | OncLive

The FDA has approved luspatercept-aamt (Reblozyl) for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell transfusions.

Original Article: FDA Approves Luspatercept for Beta Thalassemia–Associated Anemia

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Luspatercept for Beta Thalassemia–Associated Anemia"

Quick Search

Relevant Topic

Blood
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...